A Phase 3 interventional study of Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 1, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 85 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 39th largest by enrollment of the 1,242 interventional ones that give a count, is one of 76 that started in 2017, is one of 147 in phase 3, and was the 812th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 76 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 576 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
This study is registered under Gan and Lee Pharmaceuticals, USA, one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan and Lee Pharmaceuticals, USA is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
Gan & Lee Pharmaceuticals has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
•To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity
Secondary Objective:
Immunogenicity:
Safety:
•To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.
Efficacy:
•To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gan \& Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
Biological: Gan & Lee Insulin Glargine Injection
Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
Biological: Lantus®
Route of administration: subcutaneous injection
Route of administration: subcutaneous injection
Treatment-induced Anti-Insulin Antibody (TI-AIA)
TI-AIA is the Composite of Newly Confirmed Positive AIA or Important-Increase in AIA titer
Time frame: Assessed up to Week 26
Glycosylated Hemoglobin HbA1c
The change between baseline (CFB) in HbA1c and at 26 weeks
Time frame: Assessed up to Week 26
Number of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline
The number of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.
Time frame: Assessed up to Week 26
Number of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline.
The number of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to 26 weeks.
Time frame: Up to Week 26
Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline
The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.
Time frame: Assessed up to Week 26
Number of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline.
The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin neutralizing antibodies after baseline and up to visit Week 26.
Time frame: Up to Week 26
Number of Subjects With Confirmed Positive AIA After Baseline.
The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.
Time frame: Up to Week 26
Postbaseline FBG Control
The number of subjects who achieve an FBG test result of ≤ 6.0 mmol/L at visit Week 26.
Time frame: Up to Week 26
HbA1c Control.
The number of subjects who achieve a HbA1c of \< 7.0% at visit Week 26.
Time frame: Up to Week 26
Reviewed and approved by each IRB.
| Milestone | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Started | 287 | 289 |
| Completed | 258 | 255 |
| Not completed | 29 | 34 |
TI-AIA is the Composite of Newly Confirmed Positive AIA or Important-Increase in AIA titer
| Titers | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Treatment-induced Anti-Insulin Antibody (TI-AIA) | 4.8 ± 88.88 | 42.5 ± 332.90 |
The change between baseline (CFB) in HbA1c and at 26 weeks
| Percent of total hemoglobin | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Glycosylated Hemoglobin HbA1c | -0.08 ± 0.072 | 0.00 ± 0.061 |
The number of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Number of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline | 63 | 59 |
The number of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to 26 weeks.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Number of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline. | 11 | 14 |
The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.
| Titers | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline | 4.8 ± 88.88 | -42.5 ± 332.90 |
The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin neutralizing antibodies after baseline and up to visit Week 26.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Number of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline. | 13 | 16 |
The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Number of Subjects With Confirmed Positive AIA After Baseline. | 102 | 103 |
The number of subjects who achieve an FBG test result of ≤ 6.0 mmol/L at visit Week 26.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Lack of Postbaseline FBG control | 248 | 247 |
| Sufficient Postbaseline FBG control | 39 | 42 |
The number of subjects who achieve a HbA1c of \< 7.0% at visit Week 26.
| Participants | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| Lack of Postbaseline HbA1c Control | 241 | 245 |
| Sufficient Postbaseline HbA1c Control | 46 | 44 |
Collected over 26-weeks. Non-serious events are listed at a 0.3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gan & Lee Insulin Glargine Injection | 0/287 (0%) | 10/287 (3.5%) | 160/287 (55.7%) |
| Lantus® | 1/289 (0.3%) | 14/289 (4.8%) | 161/289 (55.7%) |
| Event | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 3/287 | 1/289 |
| Acute kidney injuryRenal and urinary disorders | 0/287 | 2/289 |
| DepressionPsychiatric disorders | 0/287 | 2/289 |
| Benign neoplasm of spinal cordMusculoskeletal and connective tissue disorders | 1/287 | 0/289 |
| Carotid artery occlusionBlood and lymphatic system disorders | 1/287 | 0/289 |
| CellulitisSkin and subcutaneous tissue disorders | 1/287 | 0/289 |
| Diabetic footMetabolism and nutrition disorders | 1/287 | 0/289 |
| GangreneInfections and infestations | 1/287 | 0/289 |
| Lower limb fractureMusculoskeletal and connective tissue disorders | 1/287 | 0/289 |
| Post procedural infectionGeneral disorders | 1/287 | 0/289 |
| Event | Gan & Lee Insulin Glargine Injection | Lantus® |
|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 158/287 | 161/289 |
| Weight increaseInvestigations | 3/287 | 1/289 |
| FatigueGeneral disorders | 3/287 | 0/289 |
| HyperglycemiaMetabolism and nutrition disorders | 2/287 | 1/289 |
| Blood creatine phosphokinase increasedMetabolism and nutrition disorders | 1/287 | 0/289 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/287 | 0/289 |
| DizzinessNervous system disorders | 1/287 | 0/289 |
| Face oedemaSkin and subcutaneous tissue disorders | 1/287 | 0/289 |
| Foot FractureMusculoskeletal and connective tissue disorders | 1/287 | 0/289 |
| Herpes zosterSkin and subcutaneous tissue disorders | 1/287 | 0/289 |
All Subjects Assigned randomly to treatment (full analysis set).
| Age, Categorical(Participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 256 | 252 | 508 |
| >=65 years | 31 | 37 | 68 |
| Age, Continuous(Years) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Mean | 45.7 ± 13.96 | 46.7 ± 14.46 | 46.2 ± 14.21 |
| Sex: Female, Male(Participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Female | 103 | 112 | 215 |
| Male | 184 | 177 | 361 |
| Ethnicity (NIH/OMB)(Participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 16 | 39 |
| Not Hispanic or Latino | 259 | 272 | 531 |
| Unknown or Not Reported | 5 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 6 | 7 | 13 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 13 | 14 | 27 |
| White | 262 | 265 | 527 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Hungary | 20 | 21 | 41 |
| United States | 151 | 150 | 301 |
| Czechia | 24 | 25 | 49 |
| Poland | 37 | 37 | 74 |
| Germany | 29 | 28 | 57 |
| Spain | 26 | 28 | 54 |
| Anti-Insulin Antibodies (AIA)(Participants) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Negative | 236 | 239 | 475 |
| Positive | 49 | 48 | 97 |
| Nonreportable | 0 | 2 | 2 |
| Missing | 2 | 0 | 2 |
| Body Mass Index (BMI)(kg/m2) | Gan & Lee Insulin Glargine Injection | Lantus® | Total |
|---|---|---|---|
| Mean | 27.01 ± 3.875 | 27.11 ± 4.237 | 27.06 ± 4.058 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Aug 2019, 21 months.
Results were first posted in May 2024, 4 years 8 months after primary completion. A results delay was requested in Jul 2020.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gan and Lee Pharmaceuticals, USA →